Similar Posts
Norwegian Cruise Line Sets Sail on Record Bookings Raised EPS
Key Points Norwegian Cruise Line reported a Q1 2024 EPS beat of nine cents and revenue growth of 20.3% YOY to $2.19 billion, falling short of $2.23 billion. Norwegian Cruise Line raised its full-year 2024 EPS estimates twice in May to $1.43 versus $1.26 consensus estimates. Norwegian Cruise Line raised its net yield growth rate…
GQG – GQG Partners Inc
Star stockpicker primes billion-dollar ASX payday QUOTE The listing of Florida asset manager GQG Partners on the ASX this month will be the biggest of the year, linking local investors to one of the top pandemic winners in the funds management industry and delivering a multi-billion dollar windfall to the stockpicker at the heart of…
PTC Completes Kepware & ThingWorx Sale, Raises FY2026 Free Cash Flow View and Details Buybacks
PTC (NASDAQ:PTC) used an investor update call to discuss the completed divestiture of its Kepware and ThingWorx businesses and to outline how the transaction affects fiscal 2026 guidance, cash flow expectations, and capital allocation priorities. Chief Financial Officer Jen D’Errico said the compan Source link
Is 2024 Finally the Year for a BlackBerry Stock Comeback?
Image source: Getty Images BlackBerry (TSX:BB) investors are patiently waiting for the stock to stage a turnaround after wrestling with years of underperformance. In 2016, BlackBerry exited the smartphone business as it lost market share to Apple, Samsung, and a host of China-based manufacturers, including Huawei, Xiaomi, and Oppo. BlackBerry shifted its focus to provide a portfolio of software…
Market speculator Part-Time | Swing Trade Report
Oops! You don’t have access to this content. In order to view it you must purchase the subscription. For more information contact us on the Live Chat. The post Market speculator Part-Time | Swing Trade Report appeared first on Bulls on Wall Street. Source link
Dr Reddy’s Ends Flat on Immutep Cancer Therapy Tie-Up
December 8, 2025December 8, 2025 Shares of Dr Reddy’s Laboratories Ltd ended flat on 8th December, even as the company announced that it has entered into a strategic collaboration and exclusive licensing agreement with Immutep SAS to develop and commercialise Eftilagimod Alfa (efti) across multiple global markets. Dr Reddy’s…
